EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular modulators of cyclin-dependent kinase 4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening

Surender Surender iD, Lara Annina Haeusser iD, Laurence Kuhlburger, Foteini Tsiami iD, Nihal Olcay Dogan iD, Louise Maise iD, Sven Nahnsen iD, Susanne Beck, Daniel Josef Merk iD, Ghazaleh Tabatabai iD

Neuro-Oncology · 01.08.2026 · 28 (8) · 1904-1920

DOI: 10.1093/neuonc/noag093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 04.05.2026. Verfasst von Surender Surender und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital Tübingen, Eberhard Ka…. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Glioma, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Else Kröner Fresenius Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma harbors frequent alterations in the retinoblastoma pathway, providing a genetic rationale for therapeutic targeting with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The NOA-20 trial did not reveal a progression-free survival benefit of CDK4/6 inhibition plus radiation therapy in newly diagnosed, O6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma. In fact, CDK4/6 inhibitor monotherapy has not demonstrated efficacy in solid tumors. We aimed at discovering response modulators to CDK4/6 inhibition, paving the way for rational combination therapies.

Methods

We conducted genome-wide CRISPR-Cas9 screens in human glioma cell lines and stem-like cells (LN229, LN18, LNZ308, T98G, and GS-9) under CDK4/6 inhibition, employing knockout (Brunello library) and activation strategies (Calabrese library), followed by genetic and pharmacological validation of selected candidate genes in vitro and ex vivo (primary cultures) as well as the investigation of 1 functionally instructed combination therapy in vivo.

Results

Loss of AMBRA1 and gain of function of CCNE1 reduced sensitivity to CDK4/6 inhibition in glioma cells, whereas disruption of checkpoint kinase 1 (CHEK1) or FAM122A resulted in synthetic lethality in combination with CDK4/6 inhibition. AMBRA1-deficient glioma cells exhibited increased sensitivity to CHK1 inhibition, revealing a context-specific vulnerability. Combined inhibition of CHK1 and CDK4/6 led to synergistic antiglioma activity in vitro, ex vivo, and in vivo.

Conclusions

Our data identify AMBRA1, CCNE1, CHEK1, and FAM122A as potential molecular modifiers of CDK4/6 inhibition response in experimental glioma and provide a biological rationale for combinatorial targeting with CDK4/6 inhibition in glioblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6GliomaProtein Kinase InhibitorsCRISPR-Cas SystemsBrain NeoplasmsHumansAnimalsMiceCell ProliferationCheckpoint Kinase 1ApoptosisOncogene ProteinsCell Line, TumorCyclin E

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6CDK4 protein, humanProtein Kinase InhibitorsCDK6 protein, humanCheckpoint Kinase 1Oncogene ProteinsCCNE1 protein, humanCyclin E

Autor:innen und Institutionen

  • Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany.
  • Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", Eberhard Karls University, Tübingen, Germany.
  • German Cancer Consortium (DKTK), Partner Site Tübingen, A Partnership Between DKFZ and University Hospital Tübingen, Tübingen, Germany.
  • Quantitative Biology Center, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Biomedical Data Science, Department of Computer Science, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen Stuttgart, Eberhard Karls University, Tübingen, Germany.

ORCID-Profile: Surender Surender, Lara Annina Haeusser, Foteini Tsiami, Nihal Olcay Dogan, Louise Maise, Sven Nahnsen, Daniel Josef Merk, Ghazaleh Tabatabai

Förderung

  • Else Kröner Fresenius Stiftung

Zitieren

APA

Surender, S., Haeusser, L. A., Kuhlburger, L., Tsiami, F., Dogan, N. O., Maise, L., Nahnsen, S., Beck, S., Merk, D. J., & Tabatabai, G. (2026). Molecular modulators of cyclin-dependent kinase 4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening. Neuro-Oncology, 28(8), 1904-1920. https://doi.org/10.1093/neuonc/noag093

Vancouver

Surender S, Haeusser LA, Kuhlburger L, Tsiami F, Dogan NO, Maise L, et al. Molecular modulators of cyclin-dependent kinase 4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening. Neuro-Oncology. 2026;28(8):1904-1920. doi:10.1093/neuonc/noag093

BibTeX
@article{Surender2026,
  author = {Surender, Surender and Haeusser, Lara Annina and Kuhlburger, Laurence and Tsiami, Foteini and Dogan, Nihal Olcay and Maise, Louise and Nahnsen, Sven and Beck, Susanne and Merk, Daniel Josef and Tabatabai, Ghazaleh},
  title = {Molecular modulators of cyclin-dependent kinase 4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening},
  journal = {Neuro-Oncology},
  year = {2026},
  volume = {28},
  number = {8},
  pages = {1904--1920},
  doi = {10.1093/neuonc/noag093}
}
Kostenlos starten →